Autoantibodies as Predictors for Clinical Outcome and Toxicity for Immunotherapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36106401.
- Also identified by DOI 10.1158/1078-0432.CCR-22-1664 and PMC identifier 9494631.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Peripheral blood autoantibody signatures might be useful biomarkers of immunotherapy outcome. Signatures predicting melanoma recurrence and toxicity during adjuvant immunotherapy were recently presented. Whether autoantibodies are bystanders or have a pathophysiologic role is unknown, and further efforts are needed to investigate potential mechanisms and determine causation. See related article by Johannet et al., p. 4121.
Medical subject headings
- Autoantibodies
- Melanoma